Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma

Chimeric antigen receptor (CAR) T cells targeting CD19 have achieved breakthroughs in the treatment of hematological malignancies, such as relapsed/refractory non-Hodgkin lymphoma (r/rNHL); however, high rates of treatment failure and recurrence after CAR T-cell therapy are considerable obstacles to...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Tong, Chuan, Zhang, Yajing, Liu, Yang, Ji, Xingyu, Zhang, Wenying, Guo, Yelei, Han, Xiao, Ti, Dongdong, Dai, Hanren, Wang, Chunmeng, Yang, Qingming, Liu, Wanli, Wang, Yao, Wu, Zhiqiang, Han, Weidong
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596761/
https://ncbi.nlm.nih.gov/pubmed/32556247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005278
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi